Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
出版年份 2019 全文链接
标题
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-7
出版商
Informa UK Limited
发表日期
2019-03-19
DOI
10.1080/13543784.2019.1597053
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study
- (2018) William J. Sandborn et al. GASTROENTEROLOGY
- Su1799 - Pregnancy Outcomes in Women Exposed to Ustekinumab
- (2018) Uma Mahadevan et al. GASTROENTEROLOGY
- Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: Results from a randomised phase II biopsy substudy
- (2018) Sudha Visvanathan et al. Journal of Crohns & Colitis
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
- (2018) Paul Rutgeerts et al. GASTROENTEROLOGY
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn’s Disease
- (2017) Amy L Lightner et al. Journal of Crohns & Colitis
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- 437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry
- (2016) Uma Mahadevan et al. GASTROENTEROLOGY
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
- (2016) Geoffrey C. Nguyen et al. GASTROENTEROLOGY
- DOP072. Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes
- (2016) Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
- (2013) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pharmacology of AMG 181, a human anti-α4β7antibody that specifically alters trafficking of gut-homing T cells
- (2013) WJ Pan et al. BRITISH JOURNAL OF PHARMACOLOGY
- Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
- (2013) Lukas Niederreiter et al. CURRENT DRUG TARGETS
- Discovery and mechanism of ustekinumab
- (2012) Jacqueline M. Benson et al. mAbs
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
- (2011) Alessandra Geremia et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Autoimmune diseases induced by biological agents
- (2009) Manuel Ramos-Casals et al. AUTOIMMUNITY REVIEWS
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status
- (2007) Silke Schmechel et al. INFLAMMATORY BOWEL DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now